Imagenebio, Inc. · NASDAQ:IMA
Imagenebio — Ikena Oncology — Merger or Acquisition (December 2024)
27 slides from Imagenebio's merger presentation, Dec 23, 2024
Slide 1: Corporate Overview November 2024
Corporate Overview November 2024 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (this “Presentation”) which have been prepared by Inmagene Biopharmaceuticals (“Inmagene,” the “Company” or together with its subsidiaries, collectively referred to as the “Group”) are being delivered to a limited number of parties for discuss
Slide 3: Transaction summary
Transaction summary Overview Ikena Oncology, Inc. (Nasdaq: IKNA) to acquire 100% of outstanding equity interests of Inmagene Biopharmaceuticals, structured as a public / private merger Surviving entity name: ImageneBio Inc. Issuer of unregistered common stock in PIPE: Ikena Oncology, Inc. Leerink Pa
Slide 4: Inmagene overview
Inmagene overview Clinical stage biopharmaceutical company developing potentially differentiated therapies for the treatment of immunology and inflammatory disorders Lead program, IMG-007, is an ADCC-silenced, half-life extended, non-depleting anti-OX40 mAb Inmagene owns exclusive license for global
Slide 5: Inmagene leadership team
Inmagene leadership team Chief Medical Officer Yufang Lu, MD, PhD 20+ years in drug development and medical affairs Founder and CEO Jonathan Wang, PhD, MBA 30+ years in biotech entrepreneurship, investment and research Chief Strategic Advisor Sheila Gujrathi, MD 25+ years in drug development, biotec
Slide 6: Market potential for IMG-007 estimated at ~$5bn
Market potential for IMG-007 estimated at ~ $5bn1 Source: Inmagene analyses, GlobalData, Sanofi R&D Day and Epidemiology Appendix (12/7/23) 1. U.S., EU5 (France, Germany, UK, Spain, Italy) and Japan 2. Including celiac disease, systemic sclerosis and alopecia areata IMG-007 Indication(s) Eligible Po
Slide 7: Addressing unmet need in treatment of atopic dermatitis
Addressing unmet need in treatment of atopic dermatitis AD patients present with diverse clinical phenotypes due to heterogenous molecular endotypes Currently approved biologics target Th2 pathway (IL13, IL4), which may explain their suboptimal efficacy and safety profiles1 AD is a chronic relapsing
Slide 8: IMG-007: OX40 mAb with silenced ADCC and long half-life
IMG-007: OX40 mAb with silenced ADCC and long half-life IMG-007 antibody design Fab Fab Fc N297A Mutation Based on nonclinical and clinical evaluations, IMG-007 did not exhibit T cell depleting effect, Inmagene data on file IMG-007 SC half-life is approximately 34.7 days for a single SC dose of IMG-
Slide 9: Advantages of binding OX40 receptor versus OX40 ligand
Advantages of binding OX40 receptor versus OX40 ligand in inhibiting OX40/OX40L signaling Block OX40/L signaling in: Anti-OX40 Anti-OX40L Blood Tissues An anti-OX40 mAb can engage its target in both blood and tissues vs. an anti-OX40L mAb predominantly in tissues Targeting OX40L is limited by less e
Slide 10: IMG-007's potential advantages compared to anti-Th2 mAbs
IMG-007’s potential advantages compared to anti-Th2 mAbs Th1 Th2 Th17 Th22 Memory T Regulatory T Anti-OX40 mAb IMG-007 IMG-007 has the potential: to address more diverse clinical phenotypes by targeting a broader range of T cell subtypes than Th2 targeting biologics to provide durable pharmacodynami
Slide 11: Ph2a trial in adult patients with moderate-to-severe atopic dermatitis
IMG-007 Ph2a trial in adult patients with moderate-to-severe atopic dermatitis Mean Age, years (SD): 49.8 (15.0) Sex: Female 30.8%, Male 69.2% Mean BMI (SD): 31.4 (8.7) Race: Caucasian: 46.2%, Non-Caucasian: 53.8% Mean duration of AD, years (SD): 29.6 (19.8) Mean EASI (SD): 29.5 (13.7) Mean BSA % (S
Slide 12: IMG-007 was generally well-tolerated in Ph2a atopic dermatitis trial
IMG-007 was generally well-tolerated in Ph2a atopic dermatitis trial Participants with at least one TEAE 9 (69.2%) Study treatment related TEAEs 0 Serious AE 0 TEAE by CTCAE grade Grade 1 (Mild) 3 (23.1%) Grade 2 (Moderate) 5 (38.5%) Grade 3 (Severe) 1 (7.7%) TEAE that are infusion-related reactions
Slide 13: IMG-007: well-tolerated profile, potentially due to ADCC silencing
IMG-007: well-tolerated profile, potentially due to ADCC silencing (in AD POC studies) IMG-007 and rocatinlimab tolerability observations1 Rocatinlimab tolerability observations2 (in AD Ph2b study) Pyrexia Chills Pyrexia Chills IMG-007’s well tolerated profile may allow optimizing the dose regimens
Slide 14: Ph2a in atopic dermatitis: PK sustained well above EC90 for 24 weeks
IMG-007 Ph2a in atopic dermatitis: PK sustained well above EC90 for 24 weeks 1. EC90: The 90% maximal effective concentration for the inhibition of OX40/OX40L signaling is ~1.2 ug/mL based on in vitro assays. Inmagene data on file N numbers for Day 1, Day 8, wk2 pre-dose, wk2 post-dose, wk4 pre-dose
Slide 15: Ph2a in atopic dermatitis: rapid onset of clinical activity
IMG-007 Ph2a in atopic dermatitis: rapid onset of clinical activity, maintained after the last dose at week 4 Percent (%) change from baseline in EASI score Percent (%) change from baseline in O-SCORAD score Percent (%) change from baseline in BSA score The above charts show Mean ± Standard Error N=
Slide 16: Comparison of rocatinlimab's historical POC data and IMG-007's Ph2a data
Comparison of rocatinlimab’s historical POC data and IMG-007’s Ph2a data1 IMG-007 (~4 mg/kg)2 Rocatinlimab (10 mg/kg) 3 IV doses @Q2W % change from baseline in EASI score 1. Rocatinlimab’s historical AD proof-of-concept (POC) trial: Nakagawa H et al. J Dermatol Science 2020;99(2020):82–89. Compariso
Slide 17: Ph2a in atopic dermatitis: durable activity based on EASI responder endpoints
IMG-007 Ph2a in atopic dermatitis: durable activity based on EASI responder endpoints N=13; Patients who received rescue therapies were counted as “non-responders”. Last observation carried forward (LOCF) imputation was used for missing data, except for missing data that arises following study disco
Slide 18: Ph2a in atopic dermatitis: Th1/2/17 biomarkers reduced to healthy ranges
IMG-007 Ph2a in atopic dermatitis: Th1/2/17 biomarkers were reduced to healthy ranges Th1 Serum Proteins (Mean ± SEM) Th2 Serum Proteins (Mean ± SEM) Th17 Serum Proteins (Mean ± SEM) * p<0.05 ** p<0.01; Two-way ANOVA with Dunnett’s multiple comparisons test; SEM: standard error of the mean N numbers
Slide 19: Ph2a in atopic dermatitis: inhibition of Th1/2/17 serum markers
IMG-007 Ph2a in atopic dermatitis: inhibition of Th1/2/17 serum markers FC: fold change, Log10 (FC vs Baseline): Log10 transform of fold change vs baseline Ns at baseline, wk 1, 4, 16, and 24 were 13, 12, 11, 6 and 6, respectively Post-systemic rescue treatment results were censored from the analysi
Slide 20: IMG-007 subcutaneous formulation has been developed
IMG-007 subcutaneous formulation has been developed Inmagene has developed a subcutaneous formulation. SC formulation is expected to be used in Ph2b and later studies A SC/IV PK bridging study in healthy adults is expected to be completed in December 2024 The SC formulation is at a concentration of
Slide 21: SC PK study (interim data): robust PK profile
IMG-007 SC PK study (interim data): robust PK profile IMG-007’s SC formulation showed a robust PK profile, similar to the IV formulation A single 600 mg SC dose showed a long half-life, estimated to be ~34.7 days3 IMG-007 was well-tolerated with no reports of pyrexia or chills (Mean ±SD; semi-log sc
Slide 22: IMG-007 SC: long half-life enabling potential Q24W dosing
IMG-007 (Inmagene) Rocatinlimab (Amgen) Amlitelimab (Sanofi) Half-life2,3 (days) 34.7 (SC) 12.0 (SC) 20.3 (IV) IMG-007 SC: long half-life enabling potential Q24W dosing1 1. Q24W for maintenance therapy is projected based on data for IMG-007 from the Phase 1 studies in healthy adults (Shen Y et al. A
Slide 23: IMG-007 atopic dermatitis Ph2b planned study design
IMG-007 low dose IMG-007 low dose Randomization (1:1:1:1) Enter a separate long-term extension study or safety follow-up Placebo W-5 Screening W0 Baseline W68 W52 Primary analysis Screening Period Period 1: Placebo-controlled Treatment Period 2: Active Treatment Follow-up Period IMG-007 high dose IM
Slide 24: IMG-007 demonstrates a potential for a differentiated profile
IMG-007 demonstrates a potential for a differentiated profile 1. Nakagawa et al. Journal of Dermatological Science 99 (2020) 82–89; 2. Weidinger S et al. Br J Dermatol 2023;189:531–539. 3. Rocatinlimab data is based on Guttman-Yassky E, et al. Lancet. 2023;401(10372):204-214; Amlitelimab data is bas
Slide 25: IMG-007 has a potential for a differentiated profile
IMG-007 has a potential for a differentiated profile IMG-007 vs. rocatinlimab (Amgen)1 IMG-007 vs. amlitelimab (Sanofi) 1 Ph2a data suggests IMG-007 could potentially drive greater clinical activity than rocatinlimab Longer half-life With fewer safety concerns, IMG-007 clinical activity could potent
Slide 26: IMG-007 clinical development plan for atopic dermatitis
IMG-007 clinical development plan for atopic dermatitis Phase 1 (IV) in Healthy Adults Ph2b (SC) Dose Ranging in AD Interim EOS Primary Ph3 (SC) in AD Ph2a (IV) in AD Phase 1 (SC) in Healthy Adults PK/Safety EOS: End of study 2023 2024 2025+ 2022 2023 2024 2025 2026 2027 & + Exhibit 99.2
Slide 27: INMAG=
INMAG= Exhibit 99.2
Ikena Oncology — Merger or Acquisition (December 2024) on 6ix